Stock Events

Stock Events

Cyclerion Therapeutics 

$4.03
19
+$0.00+0% 16:21 Today

Statistics

Day High
4.25
Day Low
3.87
52W High
8.48
52W Low
1.027
Volume
7,461
Avg. Volume
26,580
Mkt Cap
17.45M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q2 2026
Next
-0.38
-0.29
-0.2
-0.11
Expected EPS
N/A
Actual EPS
N/A

Financials

-170.11%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
2.07MRevenue
-3.53MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CYCN. It's not an investment recommendation.
NVIDIA
5
NVDA
Palantir Technologies
5
PLTR
Apple
4
AAPL
Tesla
4
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Axsome Therapeutics
AXSM
Mkt Cap11.19B
Axsome Therapeutics develops novel therapies for CNS disorders, overlapping with Cyclerion's focus.
Biogen
BIIB
Mkt Cap31B
Biogen has a broad portfolio in neurology and neurodegenerative diseases, competing in similar markets as Cyclerion.
Palatin Technologies
PTN
Mkt Cap16.65M
Palatin Technologies works on treatments for diseases with a focus on CNS, posing competition in the therapeutic space.
Alkermes
ALKS
Mkt Cap8.23B
Alkermes has a focus on CNS disorders, including treatments for depression and schizophrenia, competing with Cyclerion's interests.
AMGEN
AMGN
Mkt Cap224.63B
Amgen, with its broad focus, has ventured into CNS treatments, potentially competing with Cyclerion's pipeline.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie has a growing interest in neurology and CNS disorders, directly competing with Cyclerion's research and development focus.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly has a significant presence in neurology, including Alzheimer's disease, competing in the same therapeutic area as Cyclerion.
Novartis
NVS
Mkt Cap286.78B
Novartis has a diverse portfolio that includes treatments for CNS disorders, making it a competitor.
Pfizer
PFE
Mkt Cap152.69B
Pfizer has a long history in CNS and neurology, including Alzheimer's and depression, competing in the same space as Cyclerion.

About

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.
Show more...
CEO
Regina Graul
Employees
1
Country
United States
ISIN
US23255M2044

Listings

BOATS
BOATS
CYCN.BOATS
XNAS
US
CYCN

0 Comments

Share your thoughts

FAQ

What is Cyclerion Therapeutics stock price today?▼
The current price of CYCN is $4.03 USD — it has increased by +0% in the past 24 hours. Watch Cyclerion Therapeutics stock price performance more closely on the chart.
What is Cyclerion Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Cyclerion Therapeutics stocks are traded under the ticker CYCN.
Is Cyclerion Therapeutics stock price growing?▼
CYCN stock has risen by +12.89% compared to the previous week, the month change is a +10.71% rise, over the last year Cyclerion Therapeutics has showed a +58.66% increase.
What is Cyclerion Therapeutics market cap?▼
Today Cyclerion Therapeutics has the market capitalization of 17.45M
When is the next Cyclerion Therapeutics earnings date?▼
Cyclerion Therapeutics is going to release the next earnings report on November 10, 2026.
What is Cyclerion Therapeutics revenue for the last year?▼
Cyclerion Therapeutics revenue for the last year amounts to 2.07M USD.
What is Cyclerion Therapeutics net income for the last year?▼
CYCN net income for the last year is -3.53M USD.
How many employees does Cyclerion Therapeutics have?▼
As of August 18, 2026, the company has 1 employees.
In which sector is Cyclerion Therapeutics located?▼
Cyclerion Therapeutics operates in the Health & Wellness sector.
When did Cyclerion Therapeutics complete a stock split?▼
The last stock split for Cyclerion Therapeutics was on May 16, 2023 with a ratio of 1:20.
Where is Cyclerion Therapeutics headquartered?▼
Cyclerion Therapeutics is headquartered in CAMBRIDGE, United States.